AR055603A1 - Vacuna contra la infeccion por virus del dengue - Google Patents
Vacuna contra la infeccion por virus del dengueInfo
- Publication number
- AR055603A1 AR055603A1 ARP060103502A ARP060103502A AR055603A1 AR 055603 A1 AR055603 A1 AR 055603A1 AR P060103502 A ARP060103502 A AR P060103502A AR P060103502 A ARP060103502 A AR P060103502A AR 055603 A1 AR055603 A1 AR 055603A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine
- yellow fever
- chimeric flavivirus
- dengue viruses
- virus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000710829 Dengue virus group Species 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 241000710831 Flavivirus Species 0.000 abstract 3
- 241000710772 Yellow fever virus Species 0.000 abstract 2
- 229940051021 yellow-fever virus Drugs 0.000 abstract 2
- 206010012310 Dengue fever Diseases 0.000 abstract 1
- 241000725619 Dengue virus Species 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract 1
- 229940124926 Yellow fever virus vaccine Drugs 0.000 abstract 1
- 208000025729 dengue disease Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960001515 yellow fever vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70703805P | 2005-08-10 | 2005-08-10 | |
| US71944805P | 2005-09-22 | 2005-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055603A1 true AR055603A1 (es) | 2007-08-29 |
Family
ID=37758084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103502A AR055603A1 (es) | 2005-08-10 | 2006-08-10 | Vacuna contra la infeccion por virus del dengue |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080193477A1 (enExample) |
| EP (1) | EP1924280A4 (enExample) |
| JP (1) | JP5227172B2 (enExample) |
| AR (1) | AR055603A1 (enExample) |
| AU (1) | AU2006280144B2 (enExample) |
| BR (1) | BRPI0614265A2 (enExample) |
| CA (1) | CA2618783A1 (enExample) |
| IL (1) | IL189329A (enExample) |
| MY (1) | MY151051A (enExample) |
| NO (1) | NO20081127L (enExample) |
| TW (1) | TW200740458A (enExample) |
| WO (1) | WO2007021672A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| CN102449172A (zh) * | 2009-06-01 | 2012-05-09 | 伊维拉根公司 | 施用针对登革病毒的疫苗的组合物和方法 |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| EP2834265A4 (en) | 2012-04-02 | 2015-10-14 | Univ North Carolina | METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES |
| US20150265695A1 (en) | 2012-07-24 | 2015-09-24 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| KR20150036592A (ko) | 2012-07-24 | 2015-04-07 | 사노피 파스퇴르 | 백신 조성물 |
| BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
| EP2931310A4 (en) | 2012-12-14 | 2016-05-25 | Takeda Vaccines Inc | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS |
| CA3177574C (en) * | 2013-03-15 | 2026-03-31 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for dengue virus chimeric constructs in vaccines |
| AU2015217149B2 (en) * | 2014-02-11 | 2020-09-10 | Massachusetts Institute Of Technology | Novel full spectrum anti-dengue antibody |
| ES2927797T3 (es) | 2014-09-26 | 2022-11-11 | Seqirus Uk Ltd | Vacunación de sujetos inmunocomprometidos |
| GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
| WO2018183426A1 (en) * | 2017-03-30 | 2018-10-04 | Merck Sharp & Dohme Corp. | Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids |
| JP7313345B2 (ja) | 2017-10-05 | 2023-07-24 | サノフィ・パスツール | デング熱に対するブースターワクチン接種のための組成物 |
| US11590221B2 (en) | 2018-09-05 | 2023-02-28 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| WO2021034349A1 (en) | 2019-08-16 | 2021-02-25 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis a |
| US20240076631A2 (en) | 2020-02-27 | 2024-03-07 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| EP4519847A1 (en) | 2022-05-04 | 2025-03-12 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| CN120225693A (zh) | 2022-11-18 | 2025-06-27 | 武田疫苗股份有限公司 | 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法 |
| EP4626574A1 (en) | 2022-11-29 | 2025-10-08 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6676936B1 (en) * | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| US7192593B2 (en) * | 1997-05-23 | 2007-03-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| AU1813901A (en) * | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
| AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| US6966281B1 (en) * | 2004-05-05 | 2005-11-22 | Hale James R | Internal combustion device and methods of use |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-08-09 WO PCT/US2006/030846 patent/WO2007021672A2/en not_active Ceased
- 2006-08-09 US US12/063,365 patent/US20080193477A1/en not_active Abandoned
- 2006-08-09 JP JP2008526124A patent/JP5227172B2/ja not_active Expired - Fee Related
- 2006-08-09 BR BRPI0614265-6A patent/BRPI0614265A2/pt not_active Application Discontinuation
- 2006-08-09 EP EP06800943A patent/EP1924280A4/en not_active Ceased
- 2006-08-09 AU AU2006280144A patent/AU2006280144B2/en not_active Ceased
- 2006-08-09 CA CA002618783A patent/CA2618783A1/en not_active Abandoned
- 2006-08-10 AR ARP060103502A patent/AR055603A1/es unknown
- 2006-08-10 TW TW095129386A patent/TW200740458A/zh unknown
- 2006-08-10 MY MYPI20063881 patent/MY151051A/en unknown
-
2008
- 2008-02-06 IL IL189329A patent/IL189329A/en not_active IP Right Cessation
- 2008-03-04 NO NO20081127A patent/NO20081127L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP5227172B2 (ja) | 2013-07-03 |
| AU2006280144B2 (en) | 2012-06-14 |
| TW200740458A (en) | 2007-11-01 |
| WO2007021672A2 (en) | 2007-02-22 |
| WO2007021672A3 (en) | 2007-11-22 |
| IL189329A (en) | 2015-07-30 |
| JP2009504654A (ja) | 2009-02-05 |
| AU2006280144A1 (en) | 2007-02-22 |
| NO20081127L (no) | 2008-05-07 |
| CA2618783A1 (en) | 2007-02-22 |
| US20080193477A1 (en) | 2008-08-14 |
| BRPI0614265A2 (pt) | 2011-03-22 |
| EP1924280A2 (en) | 2008-05-28 |
| MY151051A (en) | 2014-03-31 |
| IL189329A0 (en) | 2008-06-05 |
| EP1924280A4 (en) | 2008-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021003931A2 (es) | Dosis unitaria de vacuna contra el dengue y administración de esta | |
| MX340880B (es) | Vacunas mejoradas y metodos para uso de las mismas. | |
| MX2018007860A (es) | Vacunas recombinantes contra el zika. | |
| EA201490654A1 (ru) | Новые ингибиторы вирусной репликации | |
| ECSP14005678A (es) | Composiciones y métodos para tratar el virus de la hepatitis c | |
| MX2018013782A (es) | Antigenos y vacunas dirigidos contra enterovirus humanos. | |
| CL2009002207A1 (es) | Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c. | |
| BR112012000287B8 (pt) | composição farmacêutica para um inibidor de protease viral de hepatite c | |
| JP2009504654A5 (enExample) | ||
| AR061887A1 (es) | Una composicion de vacuna contra el dengue | |
| Newcomer et al. | Approved and experimental countermeasures against pestiviral diseases: bovine viral diarrhea, classical swine fever and border disease | |
| MX383416B (es) | Nueva vacuna contra la influenza porcina. | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| NZ597000A (en) | Compositions and methods for administration of vaccines against dengue virus | |
| CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
| AR093185A1 (es) | Virus prrs (sindrome reproductivo y respiratorio porcino) que induce al interferon tipo i en celulas susceptibles | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| MX2023007229A (es) | Constructo de arn. | |
| AR041964A1 (es) | Vacuna de vhc que comprende un polinucleotido | |
| CO2022017989A2 (es) | Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas | |
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
| JP2016504315A5 (enExample) | ||
| Valiakos et al. | West Nile virus: Basic principles, replication mechanism, immune response and important genetic determinants of virulence | |
| CU20120057A7 (es) | Composición vacunal contra el virus del dengue, kit y plásmido | |
| CL2013002829A1 (es) | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |